Eli Lilly And Company ((LLY)), Rigel Pharmaceuticals ((RIGL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Eli Lilly and Company, in collaboration with Rigel Pharmaceuticals, is conducting an adaptive Phase 2a/2b study titled An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis. The study aims to evaluate the efficacy and safety of LY3871801 in treating adults with active rheumatoid arthritis, a condition that significantly impacts quality of life.
Intervention/Treatment: The study tests LY3871801, an experimental oral drug, against a placebo. The drug is intended to alleviate symptoms of rheumatoid arthritis, providing a potential new treatment option for patients.
Study Design: This interventional study is randomized and uses a parallel assignment model. It is double-blind, meaning neither participants nor investigators know who receives the drug or placebo. The primary purpose is treatment-focused, aiming to assess the drug’s effectiveness.
Study Timeline: The study began on May 23, 2023. The primary completion and estimated completion dates have not been specified, but the last update was submitted on July 22, 2025. These dates are crucial for tracking progress and anticipating results.
Market Implications: The ongoing study could influence Eli Lilly and Rigel Pharmaceuticals’ stock performance, especially if LY3871801 proves effective. Success could enhance investor confidence and position the companies favorably against competitors in the rheumatoid arthritis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.